MarketInOut Stock Screener Log In | Sign Up
 

Aktis Oncology Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/12/2026
Aktis Oncology Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,027.05 mln
Float28.15 mln
Earnings Date05/11/2026

1-Year Forecast

32.65
Exceptional upside

Relative Strength

87 / 100
Strongly outperforming

Debt / Equity

0.02
Debt-free

ROE

-44.11
Deeply negative

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Business Description

Aktis Oncology is a Boston-based clinical-stage company focused on developing radioactive drug treatments that target and destroy solid tumor cancers. Its two lead candidates use a miniprotein platform to deliver a radioactive element directly to cancer cells expressing specific proteins, with one currently in Phase 1b trials across multiple cancer types including bladder, breast, and lung cancer. The company works with several research and industry partners, including Eli Lilly, to advance its pipeline.

Key Fundamentals

EPS-1.21
ROE-44.11
RPS0.10
ROIC-73.55
ROA-8.96
EBITDA, mln-38.73
EV / EBITDA-15.18
EV / EBIT-14.67
Revenue, mln5.10
EV / Revenue115

Financial Strength

Altman Z-Score9.88
1-Year Target Price32.65
Short Ratio17.11
Short % of Float16.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 16.22% 96 / 100   
1 Month 12.29% 88 / 100   
2 Months 16.59% 79 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us